Ben Kaplan, CEO of $EHVVF Ehave, said, “Ehave has set a very aggressive goal to be the industry leader in preventing negative side effects during treatment for mental health issues. Our goal is to be the Company that prevents individuals from suffering from a lifetime of flashbacks after being treated for mental health issues with these powerful molecules. We believe individuals are genetically predisposed to HPPD, which is why we will be conducting a large-scale genetic analysis to isolate an individuals’ risk profile. Ehave's engineers have integrated a series of visual processing tests into MetaHealthU to measure HPPD objectively. Under medical supervision psychedelics are extremely safe. We believe focusing Ehave’s MetaHealthU mobile application platform on determining the cause and finding a possible cure for HPPD will lead to a better understanding of these molecules as a whole."
https://finance.yahoo.com/news/ehave-announce...00934.html